ORIGINAL ARTICLE

Critical illness neuromuscular disease: clinical, electrophysiological, and prognostic aspects

B Tabarki, A Coffinières, P Van den Bergh, G Huault, P Landrieu, G Sébire

Arch Dis Child 2002;86:103–107

See end of article for authors' affiliations

Correspondence to:
Dr B Tabarki, Service de
Neuropédiatrie, Cliniques
Universitaires Saint-Luc,
Université Catholique de
Louvain, Avenue
Hippocrate 10, 1200
Brussels, Belgium;
bmilaiki@excite.fr

Accepted 16 August 2001

Background: Critical illness neuromuscular disease, which has been recognised as a distinct clinical entity in adults, remains poorly described in children.

Aims: To assess retrospectively the clinical, electrophysiological, and prognostic features of the disease.

Methods: Retrospective study in a children's university hospital.

Results: Five critically ill patients presented with generalised paralysis, associated with long lasting failure to breathe in three. The cause of the generalised paralysis was critical illness neuropathy in two, acute myopathy in two, and mixed neuromyopathy in one.

Conclusions: Neuromuscular disease should be suspected in critically ill children with muscle weakness. Because corticosteroids and muscle relaxants appear to trigger some types of intensive care unit neuromuscular disease in children, their use should be restricted or administered at the lowest doses possible.

Some children in intensive care units may develop weakness or paralysis during the course of sepsis and multiple organ failure, or when they are exposed to steroids or neuromuscular blocking agents. These conditions include critical illness polyneuropathy, acute myopathy, or both. They have been described in adulthood,^{1–17} but only anecdotally in childhood.^{18–30} Critical illness neuromuscular disease is likely to occur more often in critically ill children than previously thought. This study describes five children with critical illness neuromuscular disease with respect to clinical, electrophysiological, and prognostic features.

PATIENTS AND METHODS

We retrospectively studied five children presenting with polyneuropathy or myopathy acquired in an intensive care unit (ICU) between 1990 and 1996. The diagnosis was established clinically and confirmed by electrophysiological and/or pathological studies. Patients with aetiologically characterised chronic or acute neuromuscular conditions—such as Guillain-Barré syndrome, electrolyte imbalance, porphyria, or vitamin deficiency—were excluded. Organ failure was defined using the classical criteria.³¹ The following clinical features were registered: delay of motor recovery, duration of mechanical ventilation, and hospitalisation in the ICU. Longitudinal electrophysiological studies were conducted using standardised techniques in all patients: electromyography (EMG; resting and, if possible, voluntary contraction state), and motor and sensitive nerve conduction velocities, amplitudes, and distal latencies. A muscular biopsy was performed in patient 3. Cerebrospinal fluid (CSF) analysis and serum creatine kinase titres (CK) were also recorded. Tables 1 and 2 summarise the clinical and paraclinical data. Day 0 corresponds to day of admission in the ICU. All five children received parenteral nutritional support with glucose serum containing amino acids, electrolytes, oligoelements, vitamins (daily standard polyvitamin administration and weekly supplements of vitamins B₁₂, K, E, and H), and fat emulsion.

CASE REPORTS

Patient 1

An 8 year old girl underwent two bone marrow transplants for acute idiopathic marrow aplasia. Hepatic and cutaneous

graft versus host reactions were treated with cyclosporin, prednisone, and azathioprine. During treatment she developed septic shock with multiple organ failure and required fluid resuscitation and ventilatory support. She received midazolam, fentanyl, dopamine, ceftazidime, vancomycin, amikacin, and amoxicillin. On day 12, a flaccid paralysis predominating at the distal part of the lower limbs was observed. Deep tendon reflexes were absent. Serum CK was raised (1465 IU/l). Electrophysiological investigation on day 14 showed an axonal neuropathy (compound motor and sensory potential amplitudes were reduced, conduction velocities were normal). EMG showed fibrillation potentials and positive sharp waves in the examined muscles in a predominantly distal distribution. CSF analysis revealed meningitis: 280 cells/mm³ (90% lymphocytes), protein 2.36 g/l, glucose 1.7 mmol/l. Bacteriological and virological tests were negative. She recovered on day 15 and regained normal strength over the following two months.

Conclusion: critical illness neuropathy.

Patient 2

A 14 year old boy had a two year history of acute lymphatic leukemia B. Two months after finishing standard chemotherapy, he was admitted to the ICU with septic shock caused by *Pseudomonas aeruginosa* infection complicated by marrow aplasia and multiple organ failure requiring ventilatory support. He received ceftazidime, vancomycin, cefix, ornidazole, dopamine, and steroids (dexamethasone 1 mg/kg/day on days 0–4, followed by methylprednisolone 2 mg/kg/day on days 5–11). Intermittent doses of fentanyl and narcozep, followed by a combination of fentanyl, chlorpromazine, promethazine, and vecuronium (0.1 mg/kg/h on days 8–15) were given. On day 15, he became quadriplegic. Deep tendon reflexes were absent. He did not undergo extubation until six months later. CK and CSF were normal. Electrophysiological studies on day 21 showed severe sensorimotor axonal degeneration: low motor and sensory amplitudes, normal motor and sensory

Abbreviations: CK, creatine kinase; CSF, cerebrospinal fluid; EMG, electromyography; ICU, intensive care unit

Table 1 Clinical data

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
Age at onset (year)	8	14	8	2	8
Sex	F	M	M	F	M
Pre-existing condition	Idiopathic marrow aplasia transplanted	Lymphatic leukaemia B	–	–	Bronchopulmonary dysplasia Asthma
Antecedent	Sepsis	Meningitis relapse	Status epilepticus	Fulminant hepatitis	Status asthmaticus
Infection	+	+	+	+	+
Circulatory failure	+	+	+	+	–
Respiratory failure	+	+	+	+	+
Liver failure	–	–	+	+	–
Renal failure	+	–	+	+	–
Disseminated intravascular coagulopathy	+	+	–	+	+
Encephalopathy	+	–	+	+	–
Neuromuscular signs	Quadriplegia	Flaccid quadriplegia Ventilatory dependence	Diffuse muscle atrophy	Flaccid quadriplegia Ventilatory dependence	Flaccid quadriplegia Ventilatory dependence
Timing (days)	12	15	18	8	9
Ventilatory support (days)	15	180	40	55	20
Period spent in ICU (days)	31	180	40	61	40
Outcome	Recovery (2 months)	Sequelae, death (3 years)	Death (40 days)	Recovery (6 months)	Recovery (15 days)

nerve conduction, and complete lack of voluntary activity with needle examination. Recovery was slow and incomplete. At three months, he was only able to move his toes. Additional EMG examinations on days 43 and 81 showed initial signs of reinnervation in the upper limbs, although this was still incomplete at six months. A gradual return to normal muscle strength occurred over the next nine months in the upper limbs. In the lower limbs, muscle strength remained abnormal as a result of combined residual neuropathy and anoxic lesions of the central nervous system.

Conclusion: critical illness neuropathy.

Patient 3

An 8 year old boy was admitted to the ICU with convulsions. On examination, he was comatose, had an enlarged liver, and a temperature of 40°C. He responded with unlocalised limb flexion to pain. Vecuronium 0.05–2 mg/kg/h was started on day 4. Life threatening hyperthermia (42°C) occurred on day 5, along with circulatory and renal failure, cytolytic hepatitis, and early major amyotrophy. Electrophysiological studies on day 37 under vecuronium showed non-measurable motor nerve conduction velocity in the lower limbs as a result of complete neuromuscular blockade, normal sensory nerve conduction velocity and amplitude, and spontaneous abundant fibrillation without motor unit potential recruitment in the anterior leg muscles and the deltoid. CSF protein was slightly raised on day 0 (0.52 g/l) and day 38 (0.70 g/l) without pleocytosis. Biopsy of the lateral popliteal nerve and the lateral peroneal muscle on day 38 showed, both on transverse thin sections and on teasing studies, an acute axonal neuropathy. Wallerian degeneration affected 20–30% of large myelinated fibres and small fibres to a lesser extent. No inflammation was present. The patient died after 40 days. Postmortem examination of the brain revealed only minor and unspecific lesions.

Conclusion: mixed neuromyopathy.

Patient 4

A 2 year old girl with fulminant viral hepatitis of unknown aetiology, required ventilatory support and peritoneal dialysis followed by an emergency liver transplant. She received vancomycin, ceftazidime, ornidazole, methylprednisolone

(150 mg/m²/day from day 2, after which dosage was reduced and then stopped on day 19), azathioprine, cyclosporin (from day 9), and dopamine. Vecuronium (0.05–1 mg/kg/h) was administered from day 0. Recovery of normal mental status was observed on day 8. At the same time, she displayed flaccid quadriplegia with amimia and loss of deep tendon reflexes. Extubation could not be performed on day 10 as a result of neuromuscular weakness. Electrophysiological studies on day 10 showed distally depressed motor amplitudes, normal motor and sensory nerve conduction velocities, and, on needle examination, lack of spontaneous activity with polyphasic motor unit potentials to voluntary contraction. CSF analysis on day 8 was normal. CK was high (1286 IU/l). Neurological improvement was slow: distal mobility recovered on day 14, deep tendon reflexes on day 30. She was extubated on day 55. Two months after the transplantation, at the end of intensive care management, muscle strength was scored at 2 in the lower limbs and 3 in the upper limbs. Recovery was complete after six months. EMG (days 21 and 40) revealed brief, small amplitude, polyphasic motor unit action potentials with early recruitment.

Conclusion: critical illness myopathy.

Patient 5

This 8 year old boy presented with severe bronchopulmonary dysplasia (ventilation via tracheostomy up to the age of 4.5 years), Little's syndrome, and moderate mental retardation caused by premature birth (31st week). He was admitted to the ICU with status asthmaticus. He required assisted ventilation and was treated with methylprednisolone 2 mg/kg every six hours (on days 0–4) and intravenous salbutamol. Intermittent doses of hypnovel and vecuronium 0.1 mg/kg/h provided neuromuscular blockade on days 0–8. During the neurological recovery, he developed peritonitis caused by *Klebsiella pneumoniae* infection secondary to perforation of a duodenal ulceration. On withdrawal of the sedative (day 3) and myorelaxant (day 8), flaccid quadriplegia was observed, associated with myalgia and loss of deep tendon reflexes. Electrophysiological studies on day 13 showed normal motor and sensory nerve conduction velocities and amplitudes; needle examination identified polyphasic responses with no spontaneous activity. CK was raised (990 IU/l) and CSF analysis was normal. Ventilation was stopped on day 20. The patient's strength returned to normal in three weeks.

Conclusion: critical illness myopathy.

Table 2 Electrophysiological data

	Normal value	Patient 1	Patient 2				Patient 3	Patient 4				Patient 5
		Day 13	Day 21	Day 43	Day 81		Day 37	Day 10	Day 21	Day 40	Month 5	Day 13
Muscle relaxants	—	—	+				+	+				+
Days after withdrawal of muscle relaxant	—		6	28	66		0	2	13	32	150	5
Conduction velocity (m/s)												
Median motor	40–50	43	50	52	40.5		NR	36.5	52.5	55	55	58
Median sensory	45–55	53	45.5	54.5	51		46	41	42	46	52	50
Ulnar motor	40–50	45.5	52	40.5	NR					46		48
Peroneal motor	40–50	50	42.5	50								
Suralis	45–55		46									
Amplitude												
Median motor (mV)	>6	4.8	0.15	3.1	5.7		NR	0.25	3.5	1.14	4.7	6.4
Median sensory (µV)	>10	7.5	0.9	0.07	1.75		25	32	1.65	0.53	4.6	14
Ulnar motor (mV)	>3	1.2	0.37	0.08	NR					34		8
Peroneal motor (mV)	>5.8	4.2	0.8	1								
Suralis (µV)	>6											
Distal latency (ms)												
Median motor	<3.5	3	4.1	2.8	2.9		NR	3.1	1.9	1.8	1.4	2.5
Ulnar motor	<3.5	2.6	7.3	4.7	NR				3	3.3	1.9	2
Peroneal	<3.5											
EMG												
		Fibrillation potentials	No recruitment	Reduced recruitment	Reinnervation		Fibrillation potentials	Polyphasic motor unit potentials	Small and polyphasic motor unit potentials	Small and polyphasic motor unit potentials	Normal	Polyphasic motor unit action potentials with early recruitment
		No recruitment					No recruitment					

NR, no response.

DISCUSSION

A spectrum of neuromuscular disease with flaccid weakness in critically ill adults is now recognised. Three distinct entities have been identified: critical illness polyneuropathy, acute myopathy (acute necrotising myopathy or myopathy associated with the use of corticosteroids and muscle relaxants), or both. These entities are poorly described in children.

Critical illness polyneuropathy

This is characterised by development of neuropathy during a severe illness requiring intensive care. Twenty per cent of adult cases occur during severe infection, and 70% during multiple organ failure.^{1–3} Only eight children with critical illness polyneuropathy, aged 2–17 years (four were adolescents), have been described in the literature.^{19–23} In adults, severe loss of motor function is observed: typically flaccid quadriplegia, predominant distally and occurring after two to four weeks of ICU management.¹ Our results show a similar pattern in children, although the onset is sooner, around 10 days. In our patients (patients 1 and 2), the electrophysiological and anatomical data are those of axonal degeneration involving mainly motor but also sensory fibres, which agrees with data from the literature in adults and children.^{20–21, 23} Mortality is high in adults (50–60%) and seems to be mainly a result of the underlying primary disease.^{1–3}

Mortality seems to be less in children (one patient died out of 10 reported in the literature, including our own series). Recovery is gradual over a period of several months. Forty per cent of the cases reported in childhood present neurological sequelae, mainly related to mixed central—a result of the underlying disease—and peripheral lesions.^{19–23} The pathophysiology remains unknown. Our observations led us to consider a toxic mechanism. Cyclosporin and vincristine, administered in two patients, might be involved but do not explain the full extent of the disease in view of its severity, its rapid

onset, and the delay between this treatment and the first neurological symptoms. The hypothesis of a neuropathy resulting from graft versus host reaction suggested in one of our cases cannot be sustained. Such neuropathies are demyelinating as a result of an inflammatory mechanism leading to high protein concentrations in the CSF (more than 1 g/l).³²

Other physiopathological mechanisms have been proposed, namely drug toxicity (aminoglycosides and curare), nutritional insufficiencies, and hypoxaemia.^{1–7, 8} Several mediators of the systemic inflammatory response, especially tumour necrosis factor α , which can damage myelin and oligodendrocytes in vitro, may also play an important role in the pathogenesis of critical illness polyneuropathy.³³

Acute myopathy in intensive care unit patients

Two kinds exist. Acute necrotising myopathy of intensive care occurs in the context of sepsis or trauma. Features include sudden onset of generalised muscle weakness, high blood CK and, in some patients, myoglobinuria. EMG reveals myogenic signs. Muscle biopsy specimens show panfascicular necrosis.¹⁸ The muscular recovery is usually rapid. This myopathy seems to be the muscular counterpart of critical illness polyneuropathy and could explain the mixed signs observed in patients 1 and 3.

The second kind of myopathy is myopathy associated with corticosteroids and curare, which was first described in 1977⁹; a few anecdotal cases have been reported in the literature in children.^{24–30} In adulthood, it occurs in 18–36% of patients admitted to ICU with severe asthma and 29% of patients receiving corticosteroids and curare to treat this condition.¹⁰ Patients with status asthmaticus who developed myopathy usually receive at least the cumulative equivalent dose of 1000 g methylprednisolone. Most of these patients receive steroids in association with neuromuscular blocking agents. The problems occur when curare is withdrawn, on average on day 14.

The clinical picture for children is similar to that of adults: diffuse muscle weakness (80–90% of patients), reaching the respiratory muscles in approximately 25% of cases, and amyotrophy (50% of patients).^{24–25} In newborn infants treated with curare or infants of mothers receiving this treatment, limited joint mobility has also been described, sometimes lasting for several months.^{34–35} Electrodiagnostic studies show reduction of compound motor action potential amplitude. Nerve conduction is normal. Serum CK is mildly increased in about 50% of patients. Muscle biopsies have shown a large variety of anomalies, ranging from isolated type II fibre atrophy to a severe necrosis involving all fibre types.

Ultrastructural studies have shown a selective loss of myosin filaments in some patients.^{11–12} The prognosis is generally good in adults and children. The recovery period ranges from a few days to several months and is probably linked to the extent of the muscle lesions combined with the junction blockage, which, on its own, could account for the forms of shortest duration. Sequelae are rare but can be disabling.^{10–13–14} The evolution is very similar in childhood,^{29–30} except in neonates, who sometimes exhibit weakness and consequential muscle contracture.^{27–35} There may be several factors involved in the development of this condition. Prolonged immobilisation, which did not occur in one patient, may cause atrophy as a result of non-use, although immobilisation was not associated with the high CK or electrophysiological abnormalities, as we observed.² Muscular denervation after the use of non-depolarising blocking agents may persist for several weeks after their use is discontinued. This syndrome occurs in the context of renal or hepatic failure (patient 4), and metabolic acidosis (patients 4 and 5); it can also be caused by toxic effects (aminoglycosides).¹⁵ Development of muscular weakness after the use of curare appears to depend on the dose and usually occurs after prolonged treatment over several days or even weeks.¹⁰ Long term steroid treatment may cause chronic steroid myopathy with an indolent course, and often type II fibre atrophy without regeneration or vacuolation.^{11–16} These characteristics differ from those of myopathy associated with corticosteroids and muscle relaxants administered concurrently (patients 4 and 5).³ The toxicity of these drugs can be explained, at least in part, by the increased number of cytoplasmic receptors for corticosteroids in the muscle cells as a result of immobilisation and denervation.^{3–11} There is no specific treatment. The severity of the problem suggests that precautions should be taken when administering muscle relaxants and highlights the need for further research to determine concentrations of curare in the muscle, particularly in infants, as at this age the drug is eliminated very slowly.^{21–27} The extent of neuromuscular blockage can be evaluated clinically (adaptation to the respiratory insufflation pressure) or by using a peripheral nerve stimulator.³⁶

Conclusion

In order to evaluate the extent of neuromuscular disease in the ICU, we propose careful neurological assessment of critically ill children, particularly if there is prolonged sepsis or signs of organ failure. Normal brain stem reflexes contrasting with the absence of deep tendon reflexes may suggest the diagnosis early, which should be confirmed by measurement of CK and EMG investigation. Serial CK monitoring should be performed early after exposure to steroids or neuromuscular blocking agents. A rising CK concentration could alert the clinician to an evolving myopathy. Nerve–muscle biopsy is useful when the physician is interested in seeking a classification of neuromuscular disease. Finally, patients with these diseases usually spend prolonged periods of time in the ICU. They are therefore exposed to complications (nosocomial infections), and are more expensive to treat. Specific paediatric ICUs offer the best environment for the prevention and the early detection of critical illness neuromuscular disease.

Authors' affiliations

B Tabarki, P Van den Bergh, G Sébire, Service de neuropédiatrie et service de neurologie, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Avenue Hippocrate 10, 1200 Brussels, Belgium
A Coffinières, G Huault, P Landrieu, Service de neuropédiatrie et service de réanimation infantile, Hôpital Bicêtre, Université Paris-Sud, 78 rue du Général Leclerc 94275, Le Kremlin-Bicêtre, France

REFERENCES

- 1 Zochodne DW, Bolton CF, Wells GA. Critical illness polyneuropathy. *Brain* 1987;**110**:819–42.
- 2 Bolton CF. Neuromuscular complications of sepsis. *Intensive Care Med* 1993;**19**:S58–63.
- 3 Bolton CF, Young GB, Zochodne DW. The neurological complications of sepsis. *Ann Neurol* 1993;**33**:94–100.
- 4 Witt NJ, Zochodne DW, Bolton CF. Peripheral nerve function in sepsis and multiple organ failure. *Chest* 1991;**99**:176–84.
- 5 Chad DA, Lacomis D. Critically ill patients with newly acquired weakness: the clinicopathological spectrum. *Ann Neurol* 1994;**35**:257–9.
- 6 Lacomis D, Giuliani MJ, Van Cott A, Kramer DJ. Acute myopathy of intensive care: clinical, electromyographic, and pathological aspects. *Ann Neurol* 1996;**40**:645–54.
- 7 Barat M, Brochet B, Vital C, et al. Polyneuropathie au cours de séjours prolongés en réanimation. *Rev Neurol* 1987;**143**:823–31.
- 8 Ellie E, Laguery A. Neuropathies toxiques. In: *Neuropathies périphériques*. Paris: Doin Editeur, 1992:245.
- 9 MacFarlane IA, Rosenthal FD. Severe myopathy after status asthmaticus. *Lancet* 1977;**1**:615.
- 10 Leatherman JW, Fluegel WL, David WS, et al. Muscle weakness in mechanically ventilated patients with severe asthma. *Am J Respir Crit Care Med* 1996;**153**:1686–90.
- 11 Hirano M, Ott BR, Raps EC, et al. Acute quadriplegic myopathy: a complication of treatment with steroids, non depolarising blocking agents or both. *Neurology* 1992;**42**:2082–7.
- 12 Gutmann L, Blunenthal D, Gutmann L, Schochet SS. Acute type II myofiber atrophy in critical illness. *Neurology* 1996;**46**:819–21.
- 13 Williams TJ, O'Hehir RE, Czarni D, et al. Acute myopathy in severe acute asthma treated with intravenously administered corticosteroids. *Am Rev Respir Dis* 1988;**137**:460–3.
- 14 Barohn RJ, Jackson CE, Rogers SJ, et al. Prolonged paralysis due to non depolarising neuromuscular blocking agents and corticosteroids. *Muscle Nerve* 1994;**17**:647–54.
- 15 Segredo V, Caldwell JE, Matthay MA, et al. Persistent paralysis in critically ill patients after long-term administration of vecuronium. *N Engl J Med* 1992;**327**:524–8.
- 16 Deconinck N, Van Parijs V, Beckers-Bleux G, Van den Bergh P. Critical illness myopathy unrelated to corticosteroids or neuromuscular blocking agents. *Neuromuscul Disord* 1998;**8**:186–92.
- 17 Ramsay DA, Zochodne DW, Robertson DM, et al. A syndrome of acute severe muscle necrosis in intensive care unit patients. *J Neuropathol Exp Neurol* 1993;**52**:387–98.
- 18 Sheth RD, Bolton CF. Neuromuscular complications of sepsis in children. *J Child Neurol* 1995;**10**:346–52.
- 19 Sheth RD, Pryse-Phillips WE, Riggs JE, Bodensteiner JB. Critical illness neuromuscular disease in children manifested as ventilatory dependence. *J Pediatr* 1995;**126**:259–61.
- 20 Tsao CY, Lo WD, Mendell JR, Batley RJ. Critical illness polyneuropathy in a two years old girl with hemorrhagic shock encephalopathy syndrome. *J Child Neurol* 1995;**10**:486–8.
- 21 Heckmatt BJ, Pitt MC, Kirkham F. Peripheral neuropathy and neuromuscular blockage presenting as prolonged respiratory paralysis following critical illness. *Neuropediatrics* 1993;**24**:123–5.
- 22 Dimachkie MM, Austin SG, Slopis JM, Vriesendorp FJ. Critical illness polyneuropathy in adolescence. *J Child Neurol* 1995;**10**:409–11.
- 23 Petersen B, Schneider C, Strassburg HM, Schrod L. Critical illness neuropathy in pediatric intensive care patients. *Pediatr Neurol* 1999;**21**:749–53.
- 24 Kaplan PW, Rocha W, Sanders DB, et al. Acute steroid-induced tetraplegia following status asthmaticus. *Pediatrics* 1986;**78**:121–3.
- 25 Shahar EM, Hwang PA, Niesen CE, Murphy EG. Poliomyelitis-like paralysis during recovery from acute bronchial asthma: possible etiology and risk factors. *Pediatrics* 1991;**88**:276–9.
- 26 Benzing G, Iannaccone ST, Bove KE, et al. Prolonged myasthenic syndrome after one week of muscle relaxants. *Pediatr Neurol* 1990;**6**:190–6.
- 27 Torres CF, Maniscalco WM, Agostinelli T. Muscle weakness and atrophy following prolonged paralysis with pancuronium bromide in neonates. *Ann Neurol* 1985;**18**:403–4.
- 28 Rutledge ML, Hawkins EP, Langston C. Skeletal muscle growth failure induced in premature newborn infants by prolonged pancuronium. *J Pediatr* 1986;**109**:883–6.
- 29 Sinclair JF, Malcom GA, Stephenson JB, Halworth D. Prolonged neuromuscular blockade in an infant. *Anaesthesia* 1987;**42**:1020.

- 30 **Pascucci RC.** Prolonged weakness after extended mechanical ventilation in a child. *Crit Care Med* 1990;**18**:1181–3.
- 31 **Wilkinson JD,** Pollack MM, Ruttimann UE, *et al.* Outcome of pediatric patients with multiple organ system failure. *Crit Care Med* 1986;**14**:271–4.
- 32 **Amato AA,** Barohn RJ, Sahenk Z, *et al.* Polyneuropathy complicating bone marrow transplantation and solid organ transplantation. *Neurology* 1993;**43**:1513–18.
- 33 **Selmaj UW,** Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. *Ann Neurol* 1988;**23**:339–46.
- 34 **Jago RH.** Arthrogryposis following treatment of maternal tetanus with muscle relaxants. *Arch Dis Child* 1970;**45**:277–9.
- 35 **Sinha SK,** Levene MI. Pancuronium bromide induced joint contractures in the newborn. *Arch Dis Child* 1984;**59**:73–5.
- 36 **Viby-Mogensen J.** Monitoring neuromuscular function in the intensive care unit. *Intensive Care Med* 1993;**19**:S74–9.

Postcard from Down Under.....

The wide blue yonder

I once met someone in Wolverhampton who had never travelled as far as Birmingham, a journey I made daily—sometimes by bicycle. In addition to amazement and fascination at the different way in which people live their lives, I felt a certain smugness about my own worldliness and modern attitude to distance. This, despite sometimes finding the walk to the shops a bit of a stretch. Then I came to Australia.

Australia is a big place. This is obvious to anyone who has looked at a map, especially a Peter's projection, or a globe. However, it is worth restating: Australia is a very big place, and it is frequently unsettling to be reminded of the vast scale of this country. Some examples:

Working in Mt Isa, in the remote north west of Queensland, the consultant paediatrician and I shared on-call duties over a health district covering 209 000 square kilometers. For comparison, mainland UK is 218 476 square kilometers. However, the UK does have a few more bodies than Mt Isa District's 25 000 people. Mt Isa is about 500 km inland of Townsville which is where, some weekends, the next paediatrician after me could be found.

The paediatric grand round is teleconferenced across Queensland, sometimes with the presenter here in Brisbane, sometimes in the other centres. Cairns is the current Northern limit, which at 1600 km away is about as far as London is from Warsaw or Seville. From Cairns north to Cape York, Australia's most northern mainland point, is another 500 km.

In conversation with a patient in clinic one day, I asked where they lived, as I didn't recognise the name of the town. It turned out that they'd driven 580 km that morning, mostly on unsealed roads, to come and see me. This is the equivalent of a trip from London to Glasgow, although without the delights of the M1 or M6. They didn't ask for, or need, more than 15 minutes of my time, and were—after a light lunch—going to drive straight back home again.

In telephone conversations with people back in the UK I'm asked if I've seen Uluru (Ayer's Rock) or the Sydney Opera House yet. In my mind's eye I see the road sign a couple of kilometers from our apartment which states that Sydney is 996 km away.

I went to do an outreach clinic at the next town. I borrowed a hospital car, filled it with petrol, bought a couple of litres of water and some freshly baked bread (the latter a mandatory gift) and set off. I arrived a little over two hours later, 195 km through sun-parched outback. I'd seen no one in between, except the occasional car heading in the opposite direction. No houses, no shops, just the road and the outback for mile after hypnotic mile.

By an odd contrast, however, Australia is one of the most urban countries in the world, surpassed only by city states like Hong Kong and Singapore. Most of the population lives in the big, sprawling cities, with the vast majority of the rest clinging to the coast, from Adelaide, south via Melbourne, and then north via Sydney and Brisbane to Cairns.

Many of my colleagues here find it even stranger than I do that one of the few seats which changed hands in the 2001 British general election was on the basis of a campaign to keep open one hospital in order to prevent folk from needing to travel ten miles to another one. Of interest, though, is that of the five largest cities in Australia, three have two or more children's hospitals (or hospitals with tertiary children's services) separated by less than twenty kilometres. It is interesting to speculate—but impossible to prove—that whatever people's tolerance for distance, it is political suicide to be seen to be closing a children's hospital. It is perhaps impossible to explain to the public the wisdom of specialisation and centralisation of services, especially in the emotive world of children's illness.

Now, if you'll excuse me I'm just going for a quick bike ride to Uluru . . .

I D Wacogne

Chief Resident, Royal Children's Hospital, Brisbane